---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-129619"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2024-12-18T23:59:59+00:00"
generated_at: "2026-05-29T01:57:56.685149+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "low"
source: SEC EDGAR
---

# Cognition Therapeutics releases topline data from Phase 2 COG1201 SHIMMER study

## Summary
- Slide presentation on topline results from Phase 2 COG1201 SHIMMER study made available as Exhibit 99.1.
- Study evaluates lead candidate for Alzheimer's disease; no specific data points disclosed in the 8-K body.
- Filing dated December 18, 2024; presentation likely includes efficacy/safety findings but details are unreadable.
- Company undertakes no obligation to update the materials; investor attention should review the full presentation.

## SEC filing metadata
- accession: 0001104659-24-129619
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2024-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465924129619/0001104659-24-129619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465924129619/tm2431405d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-129619
- JSON: https://secwatch.observer/filing/0001104659-24-129619.json
- Plain text: https://secwatch.observer/filing/0001104659-24-129619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.